Aprea Therapeutics (APRE) Treatment of Acute Myeloid Leukemia Receives FDA Orphan Status
Go back to Aprea Therapeutics (APRE) Treatment of Acute Myeloid Leukemia Receives FDA Orphan StatusAperture Health, Inc. (NASDAQ: APRE) | Delayed: 6.07 --0 (-0%) | |||||
---|---|---|---|---|---|---|
Previous Close | $6.07 | 52 Week High | $0.08 | |||
Open | $6.07 | 52 Week Low | $0.00 | |||
Day High | $6.07 | P/E | N/A | |||
Day Low | $6.07 | EPS | $0.00 | |||
Volume | 11 |